Laser Beam Therapeutics

Company Overview

Snapshot

Founded in July 2016 by Alon Sinai and Miri Sani, Laser Beam Therapeutics operates with 1–10 employees. The company has raised $330,000 across one funding round from PipelBiz. In January 2020, the company secured equity crowdfunding from PipelBiz.

Business overview

Laser Beam Therapeutics (LBT) develops treatment solutions to enhance the prognosis for acute myocardial infarction (MI) cases. The company's core technology involves a safe, noninvasive external laser activation method designed to mobilize stem cells into the circulatory system. These activated stem cells target MI scars to reverse the scarring process. LBT's CardioZ16 Laser Device stimulates bone marrow to accelerate tissue repair, even in areas distant from the treated bone. The company operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers.

Company Intelligence Q&A

What is the primary focus of Laser Beam Therapeutics?

Laser Beam Therapeutics focuses on developing laser therapy solutions to improve the prognosis in cases of acute myocardial infarction (MI) by mobilizing stem cells to repair scarred tissue.

Who founded Laser Beam Therapeutics?

Laser Beam Therapeutics was founded by Alon Sinai, who serves as Co-founder & CEO, and Miri Sani, who is the Co-founder & VP Regulatory Affairs.

What is the CardioZ16 Laser Device?

The CardioZ16 Laser Device is a product by Laser Beam Therapeutics that uses laser light applied to the skin over a marrow-containing bone to stimulate marrow and speed up tissue repair, including in areas far from the treated bone.

When was Laser Beam Therapeutics founded?

Laser Beam Therapeutics was founded in July 2016.

What is the current operational status of Laser Beam Therapeutics?

Laser Beam Therapeutics ceased to operate in January 2024.